GSPT1 MGD
/ Huadong Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
Discovery of potent, selective, and orally bioavailable GSPT1 molecular glue degraders (MGDs) for the treatment of MYC-driven tumors
(AACR 2025)
- "A novel, selective, potent oral GSPT1 degrader was discovered and demonstrated robust anti-tumor activity in mouse xenograft tumor models as a single agent. Collectively, we have identified novel GSPT1 MGDs as promising candidates for the treatment of MYC-driven tumors."
Oncology • GSPT1 • MYC
1 to 1
Of
1
Go to page
1